Treatment of localized or locally advanced prostate cancer: The clinical use of radiotherapy

EAU Update Series

Volumn 1, Issue 1, 2003, Pages 23-31

  Bolla, Michel ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

3D conformal radiotherapy; Brachytherapy; Hormonotherapy; IMRT; Prostate cancer

Indexed keywords

CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; HORMONAL THERAPY; HUMAN; MASS SCREENING; MEDICAL RESEARCH; PELVIS LYMPH NODE; PROSTATE CARCINOMA; PUBLIC HEALTH SERVICE; REVIEW; STANDARDIZATION;

EID: 2642527685     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00006-0     Document Type: Article

References (54)

1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: Cancer Registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33: 1075-107.
2. Partin AW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Kattan MW, et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;227:1445-51.
3. National Institutes of Health Consensus Development Panel. Consensus Development Conference on the management of clinically localized prostate cancer. Natl Cancer Inst Monogr 1988;7:3-6.
4. Kupelian PA, Potters L, Ciezki JP, Reddy CA, Reutner AM, Klein EA. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2002;54(Suppl 2):S38-9 [Abstract 61].
5. Walsh PC. Radical prostatectomy for the treatment of localized prostate carcinoma. Urol Clin North Am 1980;7:583-91.
6. Scardino PT. Early detection and natural history of clinically localized prostate cancer. In: Prostate Cancer Treatment: Stage by Stage. AUA 93rd Annual Meeting, San Diego, CA, 30 May-4 June 1998. Office of Education 009872PM.
7. Abbou CC, Salomon L, Hozneck A, et al. Laparoscopic radical prostatectomy: preliminary results. Urology 2000;55:630-4.
8. Guillonneau B, Valencien G. Laparoscopic radical prostatectomy: the Montsouris experience. J Urol 2000;163:418-22.
9. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med 1999;341:1781-8.
10. Zincke H. Bilateral pelvic lymphadenectomy and radical retro-pubic prostatectomy for stage C or D1 adenocarcinoma of the prostate: possible beneficial effect of adjuvant treatment. Natl Cancer Inst Monogr 1988;7:109-15.
11. Hanks GE. External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States. Natl Cancer Inst Monogr 1988;7:75-84.
12. Kupelian PA, Katcher J, Levin HS, Klein EA. Staging T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043-52.
13. Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 2002;89:604-11.
14. Bolla M, Van Poppel H, Van Cangh PJ, Scalliet P, Van der Bogaert W, et al. Acute and late toxicity of post operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911. In: 44th Annual ASTRO Meeting, New Orleans, 6-10 October 2002. Int J Rad Oncol Biol Phys 2002;54(Suppl 2):S62 [Abstract 103].
15. Van Cangh PJ, Richard F, Lorge F. Adjuvant therapy does not cause urinary incontinence after radical prostatectomy. J Urol 1998;159: 164-6.
16. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate specific antigen levels after radical prostatectomy. J Clin Oncol 1999;17:1153-63.
17. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, et al. The biological basis and clinical application of three dimensional conformal external beam radiation therapy in carcinoma of the prostate. Sem Oncol 1994;21:580-97.
18. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
19. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Mosvas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-10.
20. Pollack AGK, Starkschall G. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
21. [21 ] MRC Radiotherapy Working Party. RT01. A randomized trial of high dose therapy in localized cancer of the prostate using conformal radiotherapy techniques. Clinical protocol. January 1998.
22. Pommier P, Carrie C, Bey P, Beckendorf V, Maingon P, Horiot JC, et al. Tolerance of dose escalation with conformal radiotherapy in prostate cancer: preliminary results of a multicentric study. Int J Radiat Oncol Biol Phys 1998;42:310.
23. Bolla M. Three dimensional conformal radiotherapy alone vs. three dimensional conformal therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study. Brussels: EORTC Data Center; 1999.
24. Leibel SA, Fuks Z, Zelefsky MJ, et al. The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994;28:7-16.
25. Asbell SO, Krall JM, Pilepich MV, et al. Elective irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-16.
26. Spaas PG, Bagshaw MA, Cox RS. The value of extended field irradiation in surgically staged carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988;15:133 [Abstract 36].
27. Rukstalis DB, Gerber GS, Vogelzang NJ, Haraf DJ, Straus FH, Chodack GW. Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases. J Urol 1994;151:670-4.
28. Lawton CA, Winter K, Byhardt R, et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 1997;38:931-9.
29. Holm HH, Juul N, Pedersen JF, et al. Transperineal seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
30. Ash D, Flynn A, Batterman J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57(3):315-21.
31. Ragde H, Blasko J, Grimm P, Kenny G, Sylvester J, Landin K. prostate cancer patients treated with brachytherapy 5 year observed biochemical disease-free survival in T1-2. J Urol 1998;159:63 [Abstract 237].
32. Potters L, Cha C, Ashley R, Barbaris H, Leibel S. Is pelvic radiation necessary in patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;42:300 [Abstract 2146].
33. Galalae RM, Kovacs G, Schultze J, et al. Long term outcome after elective irradiation on the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002;52(1):81-90.
34. Zelefsky MJ, Fuks Z, Hunt M, et al. Int J Radiat Oncol Biol Phys 2002;53:111-6.
35. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery vs. radiotherapy for stage A2 and stage B (T1-2 M0 N0) adenocarcinoma of the prostate. J Urol 1982;128:502-4.
36. Kupelian P, Katcher J, Levin H, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleaso scores. Cancer J Sci Am 1997;3:78-87.
37. Keyser D, Kupelian PA, Zippe CD, et al. Stage T1-2 prostate cancer with pre-treatment PSA level 10 ng/ml or less. Radiation therapy or surgery? Int J Radiat Oncol Biol Phys 1997;38:351-8.
38. D'Amico A, Whittington R, Kaplan I, Beard C, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pre-treatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37:1053-8.
39. Fowler FJ, Barry MJ, Lu-Yao G, Wasson JH, et al. Outcomes of external beam radiation therapy for prostate cancer: a study of medicare beneficiaries in three surveillance epidemiology and end results areas. J Clin Oncol 1996;14:2258-65.
40. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. Natl Cancer Inst Monogr 1988;7:47-60.
41. Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
42. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997;38:1067-70.
43. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NHA, Zagars GK, et al. Supra-additive apoptotic response of R3327-G rat prostate tumours to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-7.
44. Ouden D, Davidson PJT, Hop W, Schröder FH. Surgical staging and outcome in 100 patients with stage T3 prostate cancer: radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994;151:647-51.
45. Pilepich MV, Winter K, Roach M, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
46. Widmark A. Randomized trial of locally advanced aggressive prostatic cancer T3 diff grade 1-3, T1b-T2 diff grad 2-3 (optional), N0, M0 anti-androgen treatment with or without radiotherapy. Scandinavian Prostatic Cancer Group/Swedish Society for Urological Oncology; 1996.
47. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer. Lancet 2002;360:103-8.
48. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserilin. N Engl J Med 1997;337:295-300.
49. Bolla M. EORTC 22961. Long term adjuvant hormonal treatment with LHRH analogue versus no further treatment in locally advanced prostatic carcinoma treated by external irradiation and a six months combined androgen blockade. A phase III study. Brussels: EORTC Data Center; 1996.
50. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserilin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
51. Warde P. Phase III randomized trial comparing total androgen blockade versus total androgen blockade plus pelvic irradiation in clinical stage T3-4, N0, M0 adenocarcinoma of the prostate. Intergroup (NCIC CTG, CUOG, ECOG, CALGB, SWOG). Clinical Trials Group, National Cancer Institute of Canada; 1995.
52. Laverdière J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
53. Hanks GE, Lu JD, Machtay M, et al. RTOG 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000;19:327a.
54. Raghavan D, Koczwara B, Javle M, et al. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997;33:566-74.